Floatz logo

Sargramostim

Accelerated Phase Chronic Myelogenous Leukemia

National Cancer Institute (NCI)protein_peptidePhase 1/2Dormant
B
59/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
49/ 100
Competitive Position
89/ 100

Competitive context

12 Active assets in the Accelerated Phase Chronic Myelogenous Leukemia cohort.

Asset / SponsorPhaseRating
Fludarabine
University of Illinois at Chicago
Phase 2BBB
CYCLOSPORIN A
University of Michigan Rogel Cancer Center
Phase 2BBB
Cyclophosphamide
University of Illinois at Chicago
Phase 2BBB
METHOTREXATE
University of Michigan Rogel Cancer Center
Phase 2BB
TACROLIMUS
University of Michigan Rogel Cancer Center
Phase 2BB

View all 46 →

Same molecule, other indications

Sargramostim is also rated in:

cancer of unknown primary siteDormant
BBB
Indicative ·
72 / 100
View asset →
melanomaDormant
BBB
Indicative ·
72 / 100
View asset →
chronic myeloid leukemiaDormant
BBB
Indicative ·
72 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →